

COVID-19



# Information about the Pfizer-BioNTech COVID-19 Vaccine

Updated Dec. 22, 2020

Print

### General

More Information for Healthcare Professionals

**Administration Overview** 

>

# information

Name: BNT162b2

Manufacturer: Pfizer, Inc., and BioNTech

Type of vaccine: mRNA

Learn more about how COVID-19 vaccines work and get a better understanding of COVID-19 mRNA vaccines.

Number of shots: 2 shots, 21 days apart

**How given:** Shot in the muscle of the upper arm

#### Does not contain:

- Eggs
- Preservatives
- Latex

For a full list of ingredients, see Pfizer's COVID-19 Vaccine Fact Sheet for Recipients and Caregivers 
☐

#### Who should get vaccinated

 The Pfizer-BioNTech vaccine is recommended for people aged 16 years and older. Learn more about how CDC is making COVID-19 vaccine recommendations and who should be vaccinated first when supplies are limited.

#### Who should not get vaccinated

If you have had a severe allergic reaction—also known as anaphylaxis—to any
ingredient in the Pfizer-BioNTech vaccine, you should not get vaccinated.\*
Learn more about COVID-19 vaccines and rare severe allergic reactions.

\*If you have had a severe allergic reaction to other vaccines or injectable therapies, ask your doctor if you should get the Pfizer-BioNTech vaccine. Your doctor will help you decide if it is safe for you to get the Pfizer-BioNTech vaccine.

# Side effects and safety information

#### Most common side effects

In the arm where you got the shot:	Throughout the rest of your body:
• Pain	• Chills
<ul> <li>Swelling</li> </ul>	<ul> <li>Tiredness</li> </ul>
• Redness	Headache

These side effects usually start within a day or two of getting the vaccine. They might feel like flu symptoms and might even affect your ability to do daily activities, but they should go away in a few days. Get tips on what to expect after getting vaccinated.

#### Summary of safety data

- In clinical trials, reactogenicity symptoms (side effects that happen within 7 days of getting vaccinated) were common but were mostly mild to moderate.
- Side effects (such as fever, chills, tiredness, and headache) throughout the body were more common after the second dose of the vaccine.

- Most side effects were mild to moderate. However, a small number of people had severe side effects—defined as side effects affecting a person's ability to do daily activities.
- Although few people in the clinical trials went to the hospital or died, data suggest that people who got the Pfizer-BioNTech vaccine were less likely to have these more serious outcomes compared to people who got the saline placebo.
- CDC will continue to provide updates as we learn more about the safety of the Pfizer-BioNTech vaccine in real-world conditions. Learn more about vaccine safety monitoring after a vaccine is authorized or approved for use.

Learn more about safety and reactogenicity data from the clinical trials.

## Information on how well the vaccine works

- Based on evidence from clinical trials, the Pfizer-BioNTech vaccine was 95% effective at preventing laboratory-confirmed COVID-19 illness in people without evidence of previous infection.
- CDC will continue to provide updates as we learn more about how well the Pfizer-BioNTech vaccine works in real-world conditions.

# Demographic information from clinical trials

Phase 2 and 3 clinical trials for the Pfizer-BioNTech vaccine included people from the following racial and ethnic categories:

- 81.9% White
- 26.2% Hispanic/Latino
- 9.8% African American
- 4.4% Asian
- <3% other races/ethnicities</li>

#### Age and sex breakdown:

- 50.6% male
- 49.4% female
- 21.4% 65 years and older

The most frequent underlying medical conditions were obesity (35.1%), diabetes (8.4%), and pulmonary disease (7.8%).

Learn more about demographic information for people who participated in the trials.

# More Information

What to Expect After Getting a COVID-19 Vaccine

Learn more about how federal partners are ensuring the safety of COVID-19 vaccines

Learn more about the benefits of getting a COVID-19 vaccine

Last Updated Dec. 22, 2020

Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral

Diseases